TRIDENT-1/ TPX-0005

Section NCT
Category Gynecological tumors / Breast cancer, Thoracic tumors
Subcategory Breast cancer, Non-small cell lung cancer (NSCLC)
Trial Type First-Line-Therapy (Metastatic Disease/Hematology)
Description for experts This is an investigational study of a drug named Reprotrectinib that will be given to patients with advanced solid tumors with ALK, ROS1, or NTRK1-3 rearrangements. Repotrectinib will provide opportunities in clinic to stop the abnormal cell signaling of ALK/ROS1/TRKs in solid malignancies, and overcome your body’s natural resistance to treatment of advanced solid tumors harboring ALK, ROS1, or NTRK1-3 rearrangements.
Description for laymen This is a trial investigating a drug called reprotrectinib to be administered to patients with advanced solid tumors with ALK, ROS1 or NTRK1-3 rearrangements. Repotrectinib will provide opportunities in the clinic to stop aberrant cell signaling of ALK/ROS1/TRKs in solid malignancies and overcome the body's natural resistance to treatment of advanced solid tumors harboring ALK, ROS1 or NTRK1-3 rearrangements.
JSON Data { "short_title": "TRIDENT-1/ TPX-0005", "data_mode": "900", "data_mode_number": "000002053", "official_title": "A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1). ", "accrual_state": "running", "therapeutic_value": "therapeutic", "therapieansatz_value": "palliativ", "therapieintervention_value": "not_applicable", "therapielinie_value": "first", "ctgov_number": "NCT03093116", "eudract_number": "2016-003616-13", "general_contact_email": null, "general_contact_phone": null, "hauptpruefer_dd_name": "Prof. Dr. med. habil Martin Wermke", "description_laie_de": "Hierbei handelt es sich um eine Studie zur Untersuchung eines Medikaments namens Reprotrectinib, das Patienten mit fortgeschrittenen soliden Tumoren mit ALK-, ROS1- oder NTRK1-3-Rearrangements verabreicht werden soll. Repotrectinib wird in der Klinik M\u00f6glichkeiten bieten, die anomale Zellsignalisierung von ALK/ROS1/TRKs bei soliden b\u00f6sartigen Tumoren zu stoppen und die nat\u00fcrliche k\u00f6rpereigene Resistenz gegen die Behandlung von fortgeschrittenen soliden Tumoren, die ALK-, ROS1- oder NTRK1-3-Rearrangements beherbergen, zu \u00fcberwinden.", "description_laie_en": "This is a trial investigating a drug called reprotrectinib to be administered to patients with advanced solid tumors with ALK, ROS1 or NTRK1-3 rearrangements. Repotrectinib will provide opportunities in the clinic to stop aberrant cell signaling of ALK/ROS1/TRKs in solid malignancies and overcome the body's natural resistance to treatment of advanced solid tumors harboring ALK, ROS1 or NTRK1-3 rearrangements.", "description_expert_de": "Hierbei handelt es sich um eine Studie zur Untersuchung eines Medikaments namens Reprotrectinib, das Patienten mit fortgeschrittenen soliden Tumoren mit ALK-, ROS1- oder NTRK1-3-Rearrangements verabreicht werden soll. Repotrectinib wird in der Klinik M\u00f6glichkeiten bieten, die anomale Zellsignalisierung von ALK/ROS1/TRKs bei soliden b\u00f6sartigen Tumoren zu stoppen und die nat\u00fcrliche k\u00f6rpereigene Resistenz gegen die Behandlung von fortgeschrittenen soliden Tumoren, die ALK-, ROS1- oder NTRK1-3-Rearrangements beherbergen, zu \u00fcberwinden.", "description_expert_en": "This is an investigational study of a drug named Reprotrectinib that will be given to patients with advanced solid tumors with ALK, ROS1, or NTRK1-3 rearrangements. Repotrectinib will provide opportunities in clinic to stop the abnormal cell signaling of ALK/ROS1/TRKs in solid malignancies, and overcome your body\u2019s natural resistance to treatment of advanced solid tumors harboring ALK, ROS1, or NTRK1-3 rearrangements.", "rechtsgrundlage_value": "AMG", "phase_amg_value": "I", "main_cat_id": 10, "sub_cat_id": 50 }
Settings
Short name 900-000002053